Sanofi Stock

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 11:35:19 2024-05-24 EDT After market 12:03:36
89.52 EUR -0.71% Intraday chart for Sanofi 89.39 -0.15%

Financials

Sales 2024 * 46.3B 50.05B 68.74B Sales 2025 * 49.84B 53.88B 74.01B Capitalization 113B 122B 167B
Net income 2024 * 7.08B 7.66B 10.52B Net income 2025 * 8.7B 9.41B 12.93B EV / Sales 2024 * 2.58 x
Net Debt 2024 * 6.64B 7.18B 9.86B Net Debt 2025 * 2.28B 2.46B 3.38B EV / Sales 2025 * 2.31 x
P/E ratio 2024 *
16.1 x
P/E ratio 2025 *
13 x
Employees 86,088
Yield 2024 *
4.29%
Yield 2025 *
4.51%
Free-Float 87.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.70%
1 week-0.09%
Current month-3.14%
1 month+1.47%
3 months+0.50%
6 months+4.55%
Current year+0.45%
More quotes
1 week
88.54
Extreme 88.54
92.23
1 month
87.63
Extreme 87.63
94.47
Current year
84.93
Extreme 84.93
96.50
1 year
80.60
Extreme 80.6
104.32
3 years
76.45
Extreme 76.45
106.66
5 years
67.65
Extreme 67.65
106.66
10 years
62.50
Extreme 62.5
106.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 40 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 64 20-05-21
Chairman 60 22-09-01
More insiders
Date Price Change Volume
24-05-24 89.52 -0.71% 911 282
24-05-23 90.16 -0.70% 1,143,670
24-05-22 90.8 +0.89% 1,205,626
24-05-21 90 +0.94% 1,267,158
24-05-20 89.16 -0.01% 1,041,679

Real-time Euronext Paris, May 23, 2024 at 11:37 am

More quotes
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
90.16 EUR
Average target price
108.2 EUR
Spread / Average Target
+20.00%
Consensus